Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, Chris; Nilsson, Sten; Heinrich, Daniel; Helle, Svein Inge; O’Sullivan, Joe M.; Fosså, Sophie D.; Chodacki, Aleš; Wiechno, Paweł; Logue, John P; Seke, Mihalj; Widmark, Anders; Johannessen, Dag Clement; Hoskin, Peter; Bottomley, David; James, Nicholas D.; Solberg, Arne; Syndikus, Isabel; Kliment, J.; Wedel, Steffen; Boehmer, S.; Dall’Oglio, Marcos F.; Franzén, Lars; Coleman, Robert E.; Vogelzang, Nicholas J.; O'Bryan-Tear, C. Gillies; Staudacher, K.; Garcia‐Vargas, J.; Shan, Minghua; Bruland, Øyvind S.; Sartor, Oliver

doi:10.1056/nejmoa1213755

Cited by 2,740 publications

(2,364 citation statements)

References 28 publications

Supporting

Mentioning

2,204

Contrasting

Unclassified

Order By: Relevance

“…1 In the EAP study, median OS was 6.3 months in patients who received 1-4 injections and had not been reached in those who received 5-6 injections (Fig. 1).…”

Section: S145mentioning

confidence: 95%

Radionulcides

Kapoor¹,

Hotte²

2016

CUAJ

View full text Add to dashboard Cite

show abstract

“…1 In the EAP study, median OS was 6.3 months in patients who received 1-4 injections and had not been reached in those who received 5-6 injections (Fig. 1).…”

Section: S145mentioning

confidence: 95%

Radionulcides

Kapoor¹,

Hotte²

2016

CUAJ

View full text Add to dashboard Cite

show abstract

“…6 The receptor activator for nuclear factor κB ligand (RANKL) inhibitor denosumab is another bone-modulating agent proven to reduce the incidence of SREs in metastatic CRPC patients but also without survival benefit. 29,30 Radium-223, a bone-seeking calcium-mimicking alpha emitter, was shown in a RCT 31 to not only delay first symptomatic SRE, but also improve OS. Therefore, when investigating the incidence of SRE and survival in these groups of patients, the aforementioned treatments have to be taken into account.…”

Section: Discussionmentioning

confidence: 99%

“…6,30,34,38 Radium-223 appears to hold promise as it delays symptomatic SREs by 5.8 months and improves OS by 3.8 months in metastatic prostate cancer patients. 31 Further studies are needed in this field.…”

Section: Discussionmentioning

confidence: 99%

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Wong

et al. 2015

Hong Kong Med J

View full text Add to dashboard Cite

Objective:To investigate the impact of skeletalrelated events on survival in patients with metastatic prostate cancer prescribed long-term androgen deprivation therapy.Methods: This historical cohort study was conducted in two hospitals in Hong Kong. Patients who were diagnosed with metastatic prostate cancer and prescribed androgen deprivation therapy between January 2006 and December 2011 were included. Details of skeletal-related events and mortality were examined. Results:The median follow-up was 28 (range, 1-97) months. Of 119 patients, 52 (43.7%) developed skeletal-related events throughout the study, and the majority received bone irradiation for pain control. The median actuarial overall survival and cancer-specific survival for patients with skeletalrelated events were significantly shorter than those without skeletal-related events (23 vs 48 months, P=0.003 and 26 vs 97 months, P<0.001, respectively). Multivariate analysis revealed that the adjusted hazard ratio of presence of skeletal-related events on overall and cancer-specific survival was 2.73 (95% confidence interval, 1.46-5.10; P=0.002) and 3.92 (95% confidence interval, 1.87-8.23; P<0.001), respectively. A prostate-specific antigen nadir of >4 ng/mL was an independent poor prognostic factor for overall and cancer-specific survival after development of skeletal-related events (hazard ratio=10.42; 95% confidence interval, 2.10-51.66 and Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy IntroductionProstate cancer is the most common cancer diagnosed in men in developed countries. In the United States, there were 240 890 estimated new cases in 2011, accounting for 29% of all new cancers in men and over 33 000 deaths. 1 According to the Hong Kong Cancer Registry in 2012, prostate cancer was the third most common cancer in men. 2 New knowledge added by this study • Skeletal-related events (SREs) in patients with metastatic prostate cancer significantly worsen their prognosis.• The prevalence of SREs in patients with metastatic prostate cancer is high. Implications for clinical practice or policy • Medications such as bisphosphonate therapy and receptor activator for nuclear factor κB ligand inhibitor should be considered to prevent SREs in patients with metastatic prostate cancer.Hong Kong Med J 2016;22:106-15

show abstract

“…Historically, further treatment modalities have been limited, but this has changed over the last decade as a number of new and exciting chemotherapy, bone-targeted and novel hormonal agents have demonstrated significant increases in overall survival (OS) for men with progressive metastatic CRPC. [2][3][4] The optimal management and sequencing of these drugs is an increasingly complex process, involving many different disciplines in primary, secondary and palliative care and, most importantly, the specific needs, views and circumstances of each individual patient and consideration of how therapy will affect their HR-QOL.…”

Section: Wwwtrendsinmenshealthcom Trends In Urology and Men's Health mentioning

confidence: 99%